Vistagen Receives Notice Of Allowance For AV-101 Canadian Patent For Treatment Of Dyskinesia Related To Levodopa Therapy For Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
Vistagen Therapeutics (NASDAQ:VTGN) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to the use of AV-101 for reduction of dyskinesia induced by levodopa, a common treatment for Parkinson's disease. The patent, once granted, will not expire until at least 2034. The U.S. Patent and Trademark Office has already granted a related U.S. patent for Vistagen's AV-101. Preclinical data shows AV-101 significantly reduced levodopa-induced dyskinesias without adverse side effects.
July 13, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen's receipt of a Notice of Allowance for a patent related to AV-101 could potentially strengthen the company's intellectual property portfolio and increase its market competitiveness in the treatment of Parkinson's disease.
The Notice of Allowance for the AV-101 patent could potentially increase Vistagen's market competitiveness by protecting its intellectual property and potentially leading to increased revenues from the sale of AV-101. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100